NASDAQ : VTVT

vTv Therapeutics Inc. — Company profile

Healthcare · Biotechnology · United States

Last price 25.17 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 312.73M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. vTv Therapeutics Inc. was incorporated in 2015 and is headquartered in High Point, North Carolina.

Details

NamevTv Therapeutics Inc.
SectorHealthcare
IndustryBiotechnology
Employees26
Founded2015
Ipo Date2015-07-30
CeoPaul Sekhri
CountryUnited States
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IsinUS9183852048
Cusip918385204
Cik0001641489
Sic2834
Stock TypeCommon Stock
Share ClassClass A Shares

Key executives

NameTitle
Paul J. SekhriChief Executive Officer, President and Chairman of the Board
Dr. Michael Steven Tung M.B.A., M.D.Executive Vice President and Chief Financial Officer
Barry K. BrownChief Accounting Officer
Dr. Carmen Valcarce Ph.D.Chief Scientific Officer and Executive Vice President
Elizabeth M. KeileyExecutive Vice President and General Counsel
Richard S. NelsonExecutive Vice President of Corporate Development and Director
Dr. Thomas Strack M.D., Ph.D.Chief Medical Officer
Martin LafontaineChief Commercial Officer

Contact

Address3980 Premier Drive, Suite 310, High Point, North Carolina 27265, United States
Phone336 841 0300
Websitehttps://vtvtherapeutics.com